肾性贫血的治疗研究

doi:10.3969/j.issn.1671-4091.2022.01.002

摘要/Abstract

摘要： 【摘要】贫血是慢性肾脏病患者常见并发症，与患者肾脏疾病进展、远期生存、心血管不良事件等均有关。目前有许多新药可应用于临床治疗，包括低氧诱导因子脯氨酰羟化酶抑制剂、新型静脉铁剂、长效红细胞生成素等，可有效纠正贫血。本文综述了肾性贫血的治疗进展，为肾性贫血管理提供循证依据。

关键词: 慢性肾脏病, 贫血, 红细胞生成刺激剂, 低氧诱导因子脯氨酰羟化酶抑制剂

Abstract: 【Abstract】Anemia is a common complication and is related to progression of the kidney disease, longterm survival and adverse cardiovascular events in chronic kidney disease patients. Many new drugs can be clinically used to treat the anemia, including hypoxia-inducible factor prolyl hydroxylase inhibitors, new intravenous iron reagents, long-acting erythropoietin, etc. This article summarizes the progresses in the treatment of renal anemia so as to provide the evidence-based methods for clinical management of renal anemia.

Key words: Chronic kidney disease, Anemia, Erythropoiesis-stimulating agent, Hypoxia-inducible factor prolyl hydroxylase inhibitor

中图分类号:

R692

傅晓岑, 任红, 陈楠. 肾性贫血的治疗研究[J]. 中国血液净化, 2022, 21(01): 6-9.

参考文献

[1] LI Y, SHI H, WANG W M, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: First multicenter, cross-sectional study [J]. Medicine (Baltimore), 2016, 95(24): e3872.
[2] ZUO L, WANG M, HOU F, et al. Anemia Management in the China Dialysis Outcomes and Practice Patterns Study [J]. Blood Purif, 2016, 42(1): 33-43.
[3] VLAGOPOULOS P T, TIGHIOUART H, WEINER D E, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease [J]. J Am Soc Nephrol, 2005, 16(11): 3403-10.
[4] WALKER A M, SCHNEIDER G, YEAW J, et al. Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine [J]. J Am Soc Nephrol, 2006, 17(8): 2293-8.
[5] FARAG Y M, KEITHI-REDDY S R, MITTAL B V, et al. Anemia, inflammation and health-related quality of life in chronic kidney disease patients [J]. Clin Nephrol, 2011, 75(6): 524-33.
[6] BARANY P, MULLER H J. Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease [J]. Nephrol Dial Transplant, 2007, 22 Suppl 4: iv10-iv8.
[7] SINGH A K. Diabetes, anemia and CKD: Why TREAT? [J]. Curr Diab Rep, 2010, 10(4): 291-6.
[8] HUNG S C, KUO K L, PENG C H, et al. Association of fluid retention with anemia and clinical outcomes among patients with chronic kidney disease [J]. J Am Heart Assoc, 2015, 4(1): e001480.
[9] RAMANATH V, GUPTA D, JAIN J, et al. Anemia and chronic kidney disease: making sense of the recent trials [J]. Reviews on Recent Clinical Trials, 2012, 7(3): 187-96.
[10] ECKARDT K U, SCHERHAG A, MACDOUGALL I C, et al. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD [J]. J Am Soc Nephrol, 2009, 20(12): 2651-60.
[11] SZCZECH L A, BARNHART H X, INRIG J K, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes [J]. Kidney Int, 2008, 74(6): 791-8.
[12] PFEFFER M A, BURDMANN E A, CHEN C Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease [J]. N Engl J Med, 2009, 361(21): 2019-32.
[13] DRUEKE T B, PARFREY P S. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s) [J]. Kidney Int, 2012, 82(9): 952-60.
[14] NURKO S. Anemia in chronic kidney disease: causes, diagnosis, treatment [J]. Cleve Clin J Med, 2006, 73(3): 289-97.
[15] LEE K H, HO Y, TARNG D C. Iron Therapy in Chronic Kidney Disease: Days of Future Past [J]. Int J Mol Sci, 2021, 22(3).
[16] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组;. 肾性贫血诊断与治疗中国专家共识(2018修订版) [J]. 中华肾脏病杂志, 2018, 34(11): 860-6.
[17] OOI M, HIBBS S, CHEN F E. The safety of modern intravenous iron infusions in patients with rheumatoid arthritis - a review of the literature [J]. Hematology, 2020, 25(1): 108-11.
[18] GARBOWSKI M W, BANSAL S, PORTER J B, et al. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways [J]. Haematologica, 2020, Online ahead of print.
[19] AUERBACH M, HENRY D, DELOUGHERY T G. Intravenous ferric derisomaltose for the treatment of iron deficiency anemia [J]. Am J Hematol, 2021, 96(6): 727-34.
[20] PARK H, LIU X, HENRY L, et al. Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015) [J]. BMC Nephrol, 2018, 19(1): 318.
[21] NISSENSON A R, SWAN S K, LINDBERG J S, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients [J]. Am J Kidney Dis, 2002, 40(1): 110-8.
[22] AKIZAWA T, KOSHIKAWA S, IWASAKI M, et al. Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients [J]. Ther Apher Dial, 2007, 11(3): 220-6.
[23] KAPLAN J M, SHARMA N, DIKDAN S. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease [J]. Int J Mol Sci, 2018, 19(2).
[24] JOHARAPURKAR A A, PANDYA V B, PATEL V J, et al. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases [J]. J Med Chem, 2018, 61(16): 6964-82.
[25] CHEN N, HAO C, PENG X, et al. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis [J]. N Engl J Med, 2019, 381(11): 1001-10.
[26] CHEN N, HAO C, LIU B C, et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis [J]. N Engl J Med, 2019, 381(11): 1011-22.
[27] AKIZAWA T, OTSUKA T, REUSCH M, et al. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study [J]. Ther Apher Dial, 2020, 24(2): 115-25.
[28] COYNE D W, ROGER S D, SHIN S K, et al. Roxadustat for CKD-related Anemia in Non-dialysis Patients [J]. Kidney Int Rep, 2021, 6(3): 624-35.
[29] PROVENZANO R, SZCZECH L, LEONG R, et al. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials [J]. Clin J Am Soc Nephrol, 2021, 16(8): 1190-200.
[30] TANG M, ZHU C, YAN T, et al. Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat [J]. Front Pharmacol, 2021, 12: 658079.
[31] VIGANO S M, FILIPPO S D, MILIA V L, et al. Prospective randomized pilot study on the effects of two synthetic high-flux dialyzers on dialysis patient anemia [J]. Int J Artif Organs, 2012, 35(5): 346-51.
[32] SHEETZ M, BARRINGTON P, CALLIES S, et al. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease [J]. Br J Clin Pharmacol, 2019, 85(5): 935-48.